Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Overview
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AnHeart Therapeutics Inc
Bayer AG
Chugai Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
Handok Inc
PharmatrophiX Inc
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Drug Profiles
CH-7057288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larotrectinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22B10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Dormant Products
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Discontinued Products
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Sep 28, 2019: Updated alysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer
Sep 25, 2019: Preclincal results of Baoyuan’s next-generation ROS1/NTRK inhibitor AB-106 published in ture Communications
Sep 24, 2019: EMA approves Bayer’s NTRK-targetting Vitrakvi for children and adults
Sep 20, 2019: Bayer highlights new data on Vitrakvi at ESMO 2019
Sep 06, 2019: Chugai files for expanded use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic of Rozlytrek for ROS1-positive NSCLC
Sep 04, 2019: Chugai launches Rozlytrek, an Anticancer Agent for the treatment of NTRK Fusion-Positive Solid Tumors
Aug 21, 2019: ROZLYTREK (entrectinib), FDA approved for hard-to-treat NTRK fusion-positive tumors, available at Biologics by McKesson
Aug 16, 2019: FDA approves Roche Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
Aug 15, 2019: FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
Jul 30, 2019: Health Cada approves VITRAKVI (larotrectinib), the first tumour agnostic cancer treatment for advanced solid tumours harbouring an NTRK gene fusion
Jul 26, 2019: First ?histology-independent’ treatment for solid tumours with a specific gene mutation
Jun 27, 2019: Chugai obtains Approval of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic for Rozlytrek
Jun 19, 2019: Japan first to approve Roche’s tumour-agnostic medicine Rozlytrek
Jun 03, 2019: New data on larotrectinib efficacy in patients with TRK fusion cancer and primary CNS tumors or brain metastases presented at ASCO 2019
May 30, 2019: Virtual clinical trial gives entrectinib edge over crizotinib against ROS1+ non-small cell lung cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AnHeart Therapeutics Inc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Handok Inc, H2 2019
Pipeline by PharmatrophiX Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019